These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 33826784)

  • 1. Clinical Equipoise in COVID-19 Vaccine Candidate Trials.
    Dal-Ré R
    J Clin Pharmacol; 2021 Sep; 61(9):1249-1250. PubMed ID: 33826784
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 vaccine research and the trouble with clinical equipoise.
    Friesen P; Caplan AL; Miller JE
    Lancet; 2021 Feb; 397(10274):576. PubMed ID: 33539728
    [No Abstract]   [Full Text] [Related]  

  • 3. Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.
    Sisa I; Noblecilla E; Orozco F
    Lancet; 2021 Mar; 397(10277):878. PubMed ID: 33617776
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uses of equipoise in discussions of the ethics of randomized controlled trials of COVID-19 therapies.
    Nix HP; Weijer C
    BMC Med Ethics; 2021 Oct; 22(1):143. PubMed ID: 34674679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First computational design using lambda-superstrings and in vivo validation of SARS-CoV-2 vaccine.
    Martínez L; Malaina I; Salcines-Cuevas D; Terán-Navarro H; Zeoli A; Alonso S; M De la Fuente I; Gonzalez-Lopez E; Ocejo-Vinyals JG; Gozalo-Margüello M; Calvo-Montes J; Alvarez-Dominguez C
    Sci Rep; 2022 Apr; 12(1):6410. PubMed ID: 35440789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim estimates in null models of COVID-19 vaccine effectiveness.
    Lisewski AM
    Int J Infect Dis; 2021 May; 106():169-170. PubMed ID: 33746095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
    N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development and outlook on human challenge trial of vaccine].
    Han BF; Huang NH; Chen LY; Zhao TS; Liu HY; Zhang SH; Wang Y; Zheng H; Liu B; Wang C; Liu YQ; Lu QB; Cui FQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Aug; 42(8):1371-1375. PubMed ID: 34814556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronavirus (SARS-CoV-2): a systematic review for potential vaccines.
    Bhatta M; Nandi S; Dutta S; Saha MK
    Hum Vaccin Immunother; 2022 Dec; 18(1):1865774. PubMed ID: 33545014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform.
    Russo G; Pennisi M; Fichera E; Motta S; Raciti G; Viceconti M; Pappalardo F
    BMC Bioinformatics; 2020 Dec; 21(Suppl 17):527. PubMed ID: 33308153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.